SECOND MALIGNANCIES AND MULTIPLE MYELOMA. A SINGLE-INSTITUTION EXPERIENCE IN SPAIN
(Abstract release date: 05/19/16)
EHA Library. Cerda S. 06/09/16; 134874; PB1974
Dr. Seila Cerda
Contributions
Contributions
Abstract
Abstract: PB1974
Type: Publication Only
Background
Outcome of patients with Multiple Myeloma (MM) has improved significantly in the past decade. Therefore, the risk of developing second malignancies (SM) has become a relevant aspect to explore. Although the association of several treatments employed in this disease, such as alkylators, lenalidomide or radiotherapy and second malignancies is well known in the literature, subsequent neoplasms may also reflect the effect of other etiologic factors, host characteristics or environmental exposures. In previously reported series, MM patients with SM have consistently showed poorer prognosis.
Aims
Retrospective analysis of a cohort with a consistentof more than 15 years follow-up period.
Methods
We retrospectively analysed the incidence of SM in 296 consecutive patients with MM diagnosis in our institution between 1998 and 2014, focusing on epidemiological aspects as well as on survival analysis.Characteristics of patients: n= 296.
Gender: male/female: 172/124.
Median age at MM diagnosis: 72 years (39-100).
Results
44 different cancers in 43 patients (15%) were observed.
They were mostly male (69.8%) vs female (30.2%)
The median age at diagnosis was 73 years (46-94).
Different neoplasms were separated in those appearing before or synchronously (n=27; 61%) vs after the MM diagnosis (n=17; 39%) with a mean developing time to the second malignancy of 67 (0-273) and 42 months (2-161) respectively. The majority presented solid tumors (n=39; 88.6%) in contrast to hematologic neoplasms (n=5; 11.4%).
The largest group showed prostate (n=9), gynecologic (n=7), colorectal (n=6) and genitourinary (n=6) as more frequent types of cancer.
Myelodysplastic Syndrome (MDS) represented 80% of patients with hematologic processes and typically appeared after the MM diagnosis. No acute leukemia was found in our series. Figure 1
The cumulative incidence of second cancers was 2.6 % at 2 years, 10.4% at 5 years and 18.6% at 10 years.
No differences were found in overall survival between MM patients with or without an associated second malignancy (p= 0.23).
Conclusion
SM are a growing problem in cancer patients due to their larger survival.
From our data, previous and solid neoplasms are most frequent than subsequent and hematologic neoplasms in MM patients.
Further studies are necessary to assess the risk and etiology of SM in MM, although they seem not to represent a poorer outcome in terms of survival.
Session topic: E-poster
Keyword(s): Multiple myeloma, Second malignancy
Type: Publication Only
Background
Outcome of patients with Multiple Myeloma (MM) has improved significantly in the past decade. Therefore, the risk of developing second malignancies (SM) has become a relevant aspect to explore. Although the association of several treatments employed in this disease, such as alkylators, lenalidomide or radiotherapy and second malignancies is well known in the literature, subsequent neoplasms may also reflect the effect of other etiologic factors, host characteristics or environmental exposures. In previously reported series, MM patients with SM have consistently showed poorer prognosis.
Aims
Retrospective analysis of a cohort with a consistentof more than 15 years follow-up period.
Methods
We retrospectively analysed the incidence of SM in 296 consecutive patients with MM diagnosis in our institution between 1998 and 2014, focusing on epidemiological aspects as well as on survival analysis.Characteristics of patients: n= 296.
Gender: male/female: 172/124.
Median age at MM diagnosis: 72 years (39-100).
Results
44 different cancers in 43 patients (15%) were observed.
They were mostly male (69.8%) vs female (30.2%)
The median age at diagnosis was 73 years (46-94).
Different neoplasms were separated in those appearing before or synchronously (n=27; 61%) vs after the MM diagnosis (n=17; 39%) with a mean developing time to the second malignancy of 67 (0-273) and 42 months (2-161) respectively. The majority presented solid tumors (n=39; 88.6%) in contrast to hematologic neoplasms (n=5; 11.4%).
The largest group showed prostate (n=9), gynecologic (n=7), colorectal (n=6) and genitourinary (n=6) as more frequent types of cancer.
Myelodysplastic Syndrome (MDS) represented 80% of patients with hematologic processes and typically appeared after the MM diagnosis. No acute leukemia was found in our series. Figure 1
The cumulative incidence of second cancers was 2.6 % at 2 years, 10.4% at 5 years and 18.6% at 10 years.
No differences were found in overall survival between MM patients with or without an associated second malignancy (p= 0.23).
Conclusion
SM are a growing problem in cancer patients due to their larger survival.
From our data, previous and solid neoplasms are most frequent than subsequent and hematologic neoplasms in MM patients.
Further studies are necessary to assess the risk and etiology of SM in MM, although they seem not to represent a poorer outcome in terms of survival.
Session topic: E-poster
Keyword(s): Multiple myeloma, Second malignancy
Abstract: PB1974
Type: Publication Only
Background
Outcome of patients with Multiple Myeloma (MM) has improved significantly in the past decade. Therefore, the risk of developing second malignancies (SM) has become a relevant aspect to explore. Although the association of several treatments employed in this disease, such as alkylators, lenalidomide or radiotherapy and second malignancies is well known in the literature, subsequent neoplasms may also reflect the effect of other etiologic factors, host characteristics or environmental exposures. In previously reported series, MM patients with SM have consistently showed poorer prognosis.
Aims
Retrospective analysis of a cohort with a consistentof more than 15 years follow-up period.
Methods
We retrospectively analysed the incidence of SM in 296 consecutive patients with MM diagnosis in our institution between 1998 and 2014, focusing on epidemiological aspects as well as on survival analysis.Characteristics of patients: n= 296.
Gender: male/female: 172/124.
Median age at MM diagnosis: 72 years (39-100).
Results
44 different cancers in 43 patients (15%) were observed.
They were mostly male (69.8%) vs female (30.2%)
The median age at diagnosis was 73 years (46-94).
Different neoplasms were separated in those appearing before or synchronously (n=27; 61%) vs after the MM diagnosis (n=17; 39%) with a mean developing time to the second malignancy of 67 (0-273) and 42 months (2-161) respectively. The majority presented solid tumors (n=39; 88.6%) in contrast to hematologic neoplasms (n=5; 11.4%).
The largest group showed prostate (n=9), gynecologic (n=7), colorectal (n=6) and genitourinary (n=6) as more frequent types of cancer.
Myelodysplastic Syndrome (MDS) represented 80% of patients with hematologic processes and typically appeared after the MM diagnosis. No acute leukemia was found in our series. Figure 1
The cumulative incidence of second cancers was 2.6 % at 2 years, 10.4% at 5 years and 18.6% at 10 years.
No differences were found in overall survival between MM patients with or without an associated second malignancy (p= 0.23).
Conclusion
SM are a growing problem in cancer patients due to their larger survival.
From our data, previous and solid neoplasms are most frequent than subsequent and hematologic neoplasms in MM patients.
Further studies are necessary to assess the risk and etiology of SM in MM, although they seem not to represent a poorer outcome in terms of survival.
Session topic: E-poster
Keyword(s): Multiple myeloma, Second malignancy
Type: Publication Only
Background
Outcome of patients with Multiple Myeloma (MM) has improved significantly in the past decade. Therefore, the risk of developing second malignancies (SM) has become a relevant aspect to explore. Although the association of several treatments employed in this disease, such as alkylators, lenalidomide or radiotherapy and second malignancies is well known in the literature, subsequent neoplasms may also reflect the effect of other etiologic factors, host characteristics or environmental exposures. In previously reported series, MM patients with SM have consistently showed poorer prognosis.
Aims
Retrospective analysis of a cohort with a consistentof more than 15 years follow-up period.
Methods
We retrospectively analysed the incidence of SM in 296 consecutive patients with MM diagnosis in our institution between 1998 and 2014, focusing on epidemiological aspects as well as on survival analysis.Characteristics of patients: n= 296.
Gender: male/female: 172/124.
Median age at MM diagnosis: 72 years (39-100).
Results
44 different cancers in 43 patients (15%) were observed.
They were mostly male (69.8%) vs female (30.2%)
The median age at diagnosis was 73 years (46-94).
Different neoplasms were separated in those appearing before or synchronously (n=27; 61%) vs after the MM diagnosis (n=17; 39%) with a mean developing time to the second malignancy of 67 (0-273) and 42 months (2-161) respectively. The majority presented solid tumors (n=39; 88.6%) in contrast to hematologic neoplasms (n=5; 11.4%).
The largest group showed prostate (n=9), gynecologic (n=7), colorectal (n=6) and genitourinary (n=6) as more frequent types of cancer.
Myelodysplastic Syndrome (MDS) represented 80% of patients with hematologic processes and typically appeared after the MM diagnosis. No acute leukemia was found in our series. Figure 1
The cumulative incidence of second cancers was 2.6 % at 2 years, 10.4% at 5 years and 18.6% at 10 years.
No differences were found in overall survival between MM patients with or without an associated second malignancy (p= 0.23).
Conclusion
SM are a growing problem in cancer patients due to their larger survival.
From our data, previous and solid neoplasms are most frequent than subsequent and hematologic neoplasms in MM patients.
Further studies are necessary to assess the risk and etiology of SM in MM, although they seem not to represent a poorer outcome in terms of survival.
Session topic: E-poster
Keyword(s): Multiple myeloma, Second malignancy
{{ help_message }}
{{filter}}